ProMIS Neurosciences Inc. Earnings
The next earnings date for ProMIS Neurosciences Inc. is August 12, 2026.
They are scheduled to announce earnings after the market closes that day.
Analyst Estimates of ProMIS Neurosciences Inc. Earnings
| 08/12/2026 | $-1.55 |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
ProMIS Neurosciences Inc. Earnings: Historical
| 04/06/2026 | --- | $-1.26 | -516.10% |
| 03/25/2026 | Before Market | $-30.05 | -347.84% |
| 11/12/2025 | Before Market | $-8.40 | 15.92% |
| 08/13/2025 | Before Market | $-9.98 | -65.23% |
| 05/12/2025 | Before Market | $-7.35 | -70.93% |
| 03/31/2025 | --- | $0.12 | 175.00% |
| 11/14/2024 | Before Market | $10.86 | 548.76% |
| 08/08/2024 | Before Market | $-4.47 | 7.84% |
| 05/14/2024 | After Market | $-6.48 | 5.68% |
| 03/06/2024 | Before Market | $-0.29 | -7.41% |
More About ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
“ProMIS Neurosciences Inc. Earnings” Can Refer to the ProMIS Neurosciences Inc. Earnings Date
Some people say “ProMIS Neurosciences Inc. earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my ProMIS Neurosciences Inc. position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning ProMIS Neurosciences Inc. Stock on the Earnings Date
If you own ProMIS Neurosciences Inc. stock (PMN) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for ProMIS Neurosciences Inc. might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading ProMIS Neurosciences Inc. shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More ProMIS Neurosciences Inc. Earnings
You can contact us any time if you would like to ask questions about ProMIS Neurosciences Inc. earnings or anything else related to the stock market.